Compare SID & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | SRPT |
|---|---|---|
| Founded | 1941 | 1980 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 1997 | 1997 |
| Metric | SID | SRPT |
|---|---|---|
| Price | $1.75 | $21.83 |
| Analyst Decision | Strong Sell | Hold |
| Analyst Count | 1 | 29 |
| Target Price | $1.30 | ★ $26.23 |
| AVG Volume (30 Days) | 2.2M | ★ 3.7M |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,522,708,358.00 | $2,413,715,000.00 |
| Revenue This Year | $4.33 | $13.83 |
| Revenue Next Year | $0.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.02 | ★ 47.15 |
| 52 Week Low | $1.24 | $10.42 |
| 52 Week High | $1.93 | $129.84 |
| Indicator | SID | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 55.82 |
| Support Level | $1.46 | $20.76 |
| Resistance Level | $1.84 | $22.85 |
| Average True Range (ATR) | 0.07 | 1.20 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 72.86 | 70.96 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.